Related Experiment Video
Updated: Dec 15, 2025
Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis
Published on: June 19, 2021
Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
Ana Beatriz Varanda1, Ana Martins-Logrado1, Miguel Godinho Ferreira1,2
1Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Abstract:
Poly (ADP-ribose) polymerase (PARP) inhibition in BRCA-mutated cells results in an incapacity to repair DNA damage, leading to cell death caused by synthetic lethality. Within the treatment options for advanced triple negative breast cancer, the PARP inhibitor olaparib is only given to patients with BRCA1/2 mutations. However, these patients may show resistance to this drug and BRCA1/2 wild-type tumors can show a striking sensitivity, making BRCA status a poor biomarker for treatment choice. Aiming to investigate if the zebrafish model can discriminate sensitivities to olaparib, we developed zebrafish xenografts with different BRCA status and measured tumor response to treatment, as well as its impact on angiogenesis and metastasis. When challenged with olaparib, xenografts revealed sensitivity phenotypes independent of BRCA. Moreover, its combination with ionizing radiation increased the cytotoxic effects, showing potential as a combinatorial regimen. In conclusion, we show that the zebrafish xenograft model may be used as a sensitivity profiling platform for olaparib in monotherapy or in combinatorial regimens. Hence, this model presents as a promising option for the future establishment of patient-derived xenografts for personalized medicine approaches beyond BRCA status.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibition shows promise for cancer treatment. Zebrafish xenografts reveal olaparib sensitivity independent of BRCA status, suggesting a new platform for personalized medicine.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors like olaparib are used for BRCA-mutated cancers, including advanced triple-negative breast cancer.
- Treatment resistance and sensitivity in BRCA wild-type tumors highlight limitations of BRCA status as a biomarker for olaparib efficacy.
- There is a need for predictive models to guide olaparib treatment decisions beyond BRCA mutation status.
Purpose of the Study:
- To evaluate the utility of a zebrafish xenograft model in discriminating olaparib sensitivity.
- To assess tumor response, angiogenesis, and metastasis in xenografts with varying BRCA status when treated with olaparib.
- To explore the potential of combining olaparib with ionizing radiation.
Main Methods:
- Development of zebrafish xenografts with different BRCA mutation statuses.
- Treatment of xenografts with olaparib and/or ionizing radiation.
- Assessment of tumor response, angiogenesis, and metastasis following treatment.
Main Results:
- Zebrafish xenografts exhibited olaparib sensitivity phenotypes irrespective of BRCA status.
- Olaparib treatment impacted tumor angiogenesis and metastasis.
- Combination therapy with ionizing radiation demonstrated enhanced cytotoxic effects compared to monotherapy.
Conclusions:
- The zebrafish xenograft model can serve as a platform for profiling olaparib sensitivity in monotherapy and combination regimens.
- This model offers a promising approach for developing patient-derived xenografts for personalized medicine.
- Treatment decisions for olaparib may extend beyond BRCA mutation status, enabling broader patient applicability.
